Recommended follow-up, supportive care, treatment, and anticipated survival by risk category for patients with early-stage (Rai 0-I) chronic lymphocytic leukemia (CLL).
| Variable . | Low risk* . | Intermediate risk* . | High risk* . | Symptomatic* . |
|---|---|---|---|---|
| *See Figure 2. | ||||
| †Unless as part of a clinical trial of agent with favorable toxicity profile. | ||||
| From Shanafelt et al. Narrative review: initial management of newly diagnosed, early-stage chronic lymphocytic leukemia. . Reprinted with permission from the American College of Physicians. Ann Intern Med . 2006 ;145 :435 –47 | ||||
| Median expected CLL-specific survival, y | >15 | 10 | 3-8 | 2-6 |
| Median expected treatment-free interval, y | >5 | 3-4 | 1-4 | None |
| Recommended follow-up, mo | 6-12 | |||
| 6-12 | ||||
| 3-6 | Monthly during treatment | |||
| Screening for second malignant disease | Yes | Yes | Yes | No |
| Immediate treatment indicated | No† | No† | Consider clinical trial | Yes |
| Variable . | Low risk* . | Intermediate risk* . | High risk* . | Symptomatic* . |
|---|---|---|---|---|
| *See Figure 2. | ||||
| †Unless as part of a clinical trial of agent with favorable toxicity profile. | ||||
| From Shanafelt et al. Narrative review: initial management of newly diagnosed, early-stage chronic lymphocytic leukemia. . Reprinted with permission from the American College of Physicians. Ann Intern Med . 2006 ;145 :435 –47 | ||||
| Median expected CLL-specific survival, y | >15 | 10 | 3-8 | 2-6 |
| Median expected treatment-free interval, y | >5 | 3-4 | 1-4 | None |
| Recommended follow-up, mo | 6-12 | |||
| 6-12 | ||||
| 3-6 | Monthly during treatment | |||
| Screening for second malignant disease | Yes | Yes | Yes | No |
| Immediate treatment indicated | No† | No† | Consider clinical trial | Yes |